Entasis Therapeutics Holdings Inc. (ETTX)

NASDAQ: ETTX · IEX Real-Time Price · USD
2.20
0.00 (0.00%)
At close: Jun 24, 2022 4:00 PM
2.18
-0.02 (-0.91%)
After-hours: Jun 24, 2022 4:41 PM EDT
0.00%
Market Cap 105.27M
Revenue (ttm) n/a
Net Income (ttm) -51.70M
Shares Out 47.85M
EPS (ttm) -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 109,705
Open 2.18
Previous Close 2.20
Day's Range 2.18 - 2.20
52-Week Range 1.40 - 3.88
Beta 1.44
Analysts Sell
Price Target 2.04 (-7.3%)
Earnings Date Aug 10, 2022

About ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally adm... [Read more...]

Industry Biotechnology
IPO Date Sep 26, 2018
Employees 51
Stock Exchange NASDAQ
Ticker Symbol ETTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ETTX stock is "Sell." The 12-month stock price forecast is 2.04, which is a decrease of -7.27% from the latest price.

Price Target
$2.04
(-7.27% downside)
Analyst Consensus: Sell
Stock Forecasts

News

The M&A Class Action Firm Continues to Investigate Entasis Therapeutics Holdings Inc. - ETTX

New York, New York--(Newsfile Corp. - June 21, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securit...

Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel ant...

Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of Entasis Therapeuti...

Other symbols: INVA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.

NEW YORK , May 24, 2022 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of directors concerning th...

Other symbols: INVA

Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.

Shareholder Alert: Ademi LLP investigates whether Entasis Therapeutics Holdings Inc. has obtained a Fair Price in its...

MILWAUKEE , May 24, 2022 /PRNewswire/ -- Ademi LLP is investigating Entasis (Nasdaq: ETTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Innoviva.  Click he...

ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Entasis Therapeuti...

Other symbols: INVA

ETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) to Innoviva, Inc. for $2.20 per share in ...

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash.  Innoviva currently owns approximately 60% of the outstanding shares of Ent...

Other symbols: INVA

Innoviva to Acquire Entasis Therapeutics

BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative health...

Other symbols: INVA

Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conf...

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel anti...

Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update

WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development o...

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR) Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR)

Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference

WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel an...

Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update

WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel an...

Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.

WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...

Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022

WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel ant...

Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Management to host a conference call on November 4, 2021 at 8:00am ET Management to host a conference call on November 4, 2021 at 8:00am ET

Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021

WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel ant...

Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal

Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.

Entasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection Candidate

Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced topline results from its Phase 3 ATTACK trial of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetob...

Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial

WALTHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacte...

Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibac...

Making Money With Penny Stocks During a Stock Market Crash

Trading penny stocks in a down market? Here's three tips and tricks to use in your search The post Making Money With Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks...

Other symbols: LPTXREED

Why Are Entasis Therapeutics Shares Moving Higher On Thursday?

Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) stock is up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of ...